BEUDAMED
    FDA PMA FDA Class 3 30-Day Notice Accepted 🇺🇸 United States

    Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence

    PMA: P030052 · Supplement: S009 · Decision Aug 10, 2012
    View on FDA
    Classifications
    1
    FEI Numbers
    1
    Registration Numbers
    1

    Basic Information

    Device Name
    Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence
    Trade Name
    UROVYSION BLADDER CANCER KIT ASSAY
    PMA Number
    P030052
    Supplement Number
    S009
    Device Class
    FDA Class 3
    Product Code
    NSD
    Generic Name
    Test, fluorescence in situ hybridization (fish), for bladder cancer detection and monitoring for recurrence
    Medical Specialty
    Unknown
    Advisory Committee
    Pathology
    Decision
    30-Day Notice Accepted
    Decision Code
    OK30
    Decision Date
    August 10, 2012
    Date Received
    July 13, 2012
    Supplement Type
    30-Day Notice
    Supplement Reason
    Process Change - Manufacturer/Sterilizer/Packager/Supplier
    Expedited Review
    N

    Advisory Committee Statement

    ELIMINATE A SECOND CLONE IDENTITY TESTING PROCEDURE AT THE FERMENTATION STAGE FOR LSI 9P21, QUALIFY THE GENEPREP INSTRUMENT, QUALIFY THE OVERHEADMIXING SYSTEM AND VALIDATION OF MIXING PROCESS IN THE MANUFACTURE OF HYBRIDIZATION BUFFER,IMPLEMENT THE OPTICAL DENSITY READING AS AN ADDITIONAL IN PROCESS QUALITY CONTROL, VALIDATE ANEXISTING MIXING PROCESS FOR THE UROVYSION BULK SOLUTION, AND TRANSFER AN EXISTING IN-PROCESS TESTING OF LABELED DNA.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    NSD Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence